Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ertapenem + levofloxacin is a combination of two antibiotics used together, primarily in clinical or investigational settings, to treat infections caused by susceptible bacteria. Ertapenem is a carbapenem-class beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. The combination has been studied for synergistic or additive effects against various Gram-negative pathogens including *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. It may be considered in severe or resistant infections such as complicated urinary tract infections or pneumonia when monotherapy may not be sufficient[1][3][6]. Both drugs are approved individually but the fixed combination does not have an established brand name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ertapenem + levofloxacin.